BF-114
Obesity, NAFLD, NASH, Hepatocellular Carcinoma (HCC)
PreclinicalActive
Key Facts
Indication
Obesity, NAFLD, NASH, Hepatocellular Carcinoma (HCC)
Phase
Preclinical
Status
Active
Company
About Bullfrog AI
Bullfrog AI aims to transform precision medicine by applying its award-winning, graph-based AI platform to identify the right drug for the right patient at the right dose. The company operates a dual-strategy business model, advancing its own in-licensed pipeline in glioblastoma and metabolic diseases while commercializing its bfPREP™ and bfLEAP™ platforms as SaaS solutions for data harmonization and analysis. Its technology, originally developed at Johns Hopkins University Applied Physics Laboratory, is designed to uncover hidden patterns in complex, multimodal biomedical data to optimize clinical trials, discover novel targets, and identify patient subgroups.
View full company profile